The role of allogeneic SCT in primary myelofibrosis: a British Society for Blood and Marrow Transplantation study (original) (raw)

References

  1. Smith BD, Moliterno AR . Biology and management of idiopathic myelofibrosis. Curr Opin Oncol 2001; 13: 91–94.
    Article CAS Google Scholar
  2. Tefferi A . Myelofibrosis with myeloid metaplasia. N Engl J Med 2000; 342: 1255–1265.
    Article CAS Google Scholar
  3. Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009; 113: 2895–2901.
    Article CAS Google Scholar
  4. Dupriez B, Morel P, Demory JL, Lai JL, Simon M, Plantier I et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 1996; 88: 1013–1018.
    CAS PubMed Google Scholar
  5. Bachleitner-Hofmann T, Gisslinger H . The role of interferon-alpha in the treatment of idiopathic myelofibrosis. Ann Hematol 1999; 78: 533–538.
    Article CAS Google Scholar
  6. Marchetti M, Barosi G, Balestri F, Viarengo G, Gentili S, Barulli S et al. Low dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial. J Clin Oncol 2004; 22: 424–431.
    Article CAS Google Scholar
  7. Mesa RA, Steensma DP, Pardanani A, Li CY, Elliot M, Kaufmann SH et al. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood 2003; 101: 2534–2541.
    Article CAS Google Scholar
  8. Kroger N, Mesa RA . Choosing between stem cell therapy and drugs in myelofibrosis. Leukemia 2008; 22: 474–486.
    Article CAS Google Scholar
  9. Li Z, Gooley T, Applebaum FR, Deeg HJ . Splenectomy and hemopoietic stem cell transplantation for myelofibrosis. Blood 2001; 97: 2180–2181.
    Article CAS Google Scholar
  10. Ciurea SO, Sadegi B, Wilbur A, Alagiozian-Angelova V, Gaitonde S, Dobogai LC et al. Effects of extensive splenomegaly in patients with myelofibrosis undergoing a reduced intensity allogeneic stem cell transplantation. Br J Haematol 2008; 141: 80–83.
    Article Google Scholar
  11. Mesa R, Nagorney DS, Schwager S, Allred J, Tefferi A . Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic. Cancer 2006; 107: 361–370.
    Article Google Scholar
  12. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 43: 1144–1148.
    Article Google Scholar
  13. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054–1061.
    Article CAS Google Scholar
  14. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR et al. A gain-of-function mutation in JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779–1790.
    Article CAS Google Scholar
  15. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ et al. Activating muation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387–397.
    Article CAS Google Scholar
  16. Verstovsek S, Kantarjian H, Pardanani A, Thomas D, Cortes J, Mesa R et al. The JAK inhibitor, INCB018424, demonstrates durable and marked clinical responses in primary myelofibrosis (PMF) and post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood (ASH Annual Meeting Abstracts) 2008; 112: Abstract 1762.
  17. Guardiola P, Anderson JE, Bandini G, Cervantes F, Runde V, Arcese W et al. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Societe Francaise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research center Collaborative Study. Blood 1999; 93: 2831–2838.
    CAS PubMed Google Scholar
  18. Daly A, Song K, Nevill T, Nantel S, Toze C, Hogge D et al. Stem cell transplantation for myelofibrosis: a report from two canadian centers. Bone Marrow Transplant 2003; 32: 35–40.
    Article CAS Google Scholar
  19. Deeg HJ, Gooley TA, Flowers ME, Sale GE, Slattery JT, Anasetti C et al. Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood 2003; 102: 3912–3918.
    Article CAS Google Scholar
  20. Ditchkowski M, Beelen DW, Trenschel R, Koldehoff M, Elmaagacli AH . Outcome of allogeneic stem cell transplantation in patients with myelofibrosis. Bone Marrow Transplant 2004; 34: 807–813.
    Article Google Scholar
  21. Devine SM, Hoffman R, Verma A, Shah R, Bradlow BA, Stock W et al. Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. Blood 2002; 99: 2255–2258.
    Article CAS Google Scholar
  22. Snyder DS, Palmer J, Stein AS, Pullarkat V, Sahebi F, Cohen S et al. Allogeneic hematopoietic cell transplantation following reduced intensity conditioning for treatment of myelofibrosis. Biol Blood Marrow Transplant 2006; 12: 1161–1168.
    Article Google Scholar
  23. Hessling J, Kroger N, Werner M, Zabelina T, Hansen A, Kordes U et al. Dose reduced conditioning regimen followed by allogeneic stem cell transplantation in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 2002; 119: 769–772.
    Article Google Scholar
  24. Merup M, Lazarevic V, Nahi H, Andreasson B, Malm C, Nilsson L et al. Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced-intensity conditioning regimens. Br J Haematol 2006; 135: 367–373.
    Article CAS Google Scholar
  25. Kroger N, Zabelina T, Schieder H, Panse J, Ayuk F, Stute N et al. Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis. Br J Haematol 2005; 128: 690–697.
    Article Google Scholar
  26. Rondelli D, Barosi G, Bacigalupo A, Prchal JT, Popat U, Alessandrino EP et al. Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia. Blood 2005; 105: 4115–4119.
    Article CAS Google Scholar
  27. Patriarca F, Bacigalupo A, Speretto A, Isola M, Soldano F, Bruno B et al. Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano di Midollo Osseo (GITMO). Haematologica 2008; 93: 1514–1522.
    Article CAS Google Scholar
  28. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825–828.
    CAS Google Scholar
  29. Sullivan KM, Agura E, Anasetti C et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 1991; 28: 250–259.
    CAS PubMed Google Scholar
  30. Kroger N, Thiele J, Zander A, Schwertefeger R, Kobbe G, Bornhauser M et al. Rapid regression of bone marrow fibrosis after dose reduced allogeneic stem cell transplantation in patients with primary myelofibrosis. Exp Hematol 2007; 35: 1719–1722.
    Article Google Scholar

Download references